2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck.

Mignion, Lionel;Schmitz, Sandra;Michoux, Nicolas;Caignet, Xavier;Machiels, Jean-Pascal;et.al.
(2018) OncoTarget — Vol. 9, n° 47, p. 28572-28585 (2018)

Files

oncotarget-09-28572.pdf
  • Open Access
  • Adobe PDF
  • 1.66 MB
Download

Details

Authors
Show more
Abstract
We investigated changes on 2'-deoxy-2'-[18F]fluoro-D-glucose positron emission tomography (FDG-PET), diffusion-weighted magnetic resonance imaging (DW-MRI), and choline spectroscopy as early markers of cetuximab activity in squamous cell carcinoma of the head and neck (SCCHN). SCCHN patient-derived tumor xenografts models were selected based on their cetuximab sensitivity. Three models were resistant to cetuximab and two were sensitive (one was highly sensitive and the other one was moderately sensitive). Cetuximab was infused on day 0 and 7. Maximal standardized uptake values (SUVmax), apparent diffusion coefficient (ADC), and total choline pool were measured at baseline and at day 8. To investigate the possible clinical relevance of our pre-clinical findings, we also studied the SUVmax and ADC modifications induced by cetuximab in five patients. Cetuximab induced a significant decrease in SUVmax and an increase in ADC at day 8 compared to baseline in the most cetuximab-sensitive model but not in the other models. At day 8, in one resistant model, SUVmax was decreased compared to baseline and was significantly lower than the controls. Choline spectroscopy was not able to predict cetuximab activity. The five patients treated with cetuximab had a FDG-PET partial response. One patient had a partial response according to RECISTv1.1. Interestingly, this last had also an increase in ADC value above 25%. Our preclinical data support the use of PDTX to investigate imaging techniques to detect early treatment response. Our pre-clinical and clinical data suggest that DW-MRI and FDG-PET should be further investigated to predict cetuximab activity.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mignion, L., Schmitz, S., Michoux, N., Caignet, X., Goebbels, R.-M., Bol, A., Neveu Marie-Aline C., Grégoire, V., Duprez, T., Lhommel, R., Amant, F., Hermans, E., Jordan, B., & Machiels, J.-P. (2018). 2′-deoxy-2′-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. OncoTarget, 9(47), 28572-28585. https://doi.org/10.18632/oncotarget.25574 (Original work published 2018)